Cencora, Inc. Declares Quarterly Dividend of $0.60 (NYSE:COR)

Cencora, Inc. (NYSE:COR) announced a quarterly dividend on Wednesday, August 5th. Shareholders of record on Friday, August 14th will be paid a dividend of 0.60 per share on Monday, August 31st. This represents a c) dividend on an annualized basis and a yield of 0.8%. The ex-dividend date of this dividend is Friday, August 14th.

Cencora has raised its dividend payment by an average of 0.1%per year over the last three years and has increased its dividend annually for the last 15 consecutive years. Cencora has a payout ratio of 13.9% meaning its dividend is sufficiently covered by earnings. Analysts expect Cencora to earn $19.81 per share next year, which means the company should continue to be able to cover its $2.40 annual dividend with an expected future payout ratio of 12.1%.

Cencora Trading Up 3.7%

Shares of NYSE:COR traded up $11.40 during trading on Wednesday, hitting $317.68. The company had a trading volume of 2,291,352 shares, compared to its average volume of 1,536,487. The stock has a market cap of $61.81 billion, a price-to-earnings ratio of 24.36, a price-to-earnings-growth ratio of 1.71 and a beta of 0.57. The company has a debt-to-equity ratio of 3.40, a current ratio of 0.95 and a quick ratio of 0.59. The company has a fifty day simple moving average of $290.71 and a two-hundred day simple moving average of $314.85. Cencora has a one year low of $244.82 and a one year high of $377.54.

Cencora (NYSE:COR) last released its earnings results on Wednesday, August 5th. The company reported $4.48 earnings per share for the quarter, beating the consensus estimate of $4.35 by $0.13. Cencora had a return on equity of 135.20% and a net margin of 0.78%.The firm had revenue of $84.75 billion for the quarter, compared to the consensus estimate of $84.31 billion. During the same quarter in the previous year, the company posted $4.00 EPS. The company’s revenue for the quarter was up 5.1% compared to the same quarter last year. As a group, equities analysts forecast that Cencora will post 17.79 earnings per share for the current year.

Cencora News Summary

Here are the key news stories impacting Cencora this week:

• Positive Sentiment: Fiscal third-quarter adjusted EPS rose 12% year over year to $4.48, exceeding analyst estimates of approximately $4.35–$4.37. Revenue increased 5.1% to about $84.8 billion, broadly ahead of consensus in the company’s reported figures. Cencora Reports Fiscal 2026 Third Quarter Results
• Positive Sentiment: Cencora raised its fiscal 2026 adjusted EPS forecast to $17.75–$17.95 from $17.70–$17.90, signaling confidence in continued earnings momentum, while maintaining its annual sales outlook. Cencora lifts annual profit view on strong demand for specialty medicines
• Positive Sentiment: Growth in U.S. Healthcare Solutions, specialty pharmaceuticals, OneOncology and international operations supported results. The company also repurchased approximately $1 billion of stock during the quarter, potentially supporting per-share earnings and investor sentiment. Why Cencora (COR) Stock Is Up Today
• Neutral Sentiment: Analyst price targets remain mixed, but the reported median target of roughly $344.50 suggests potential upside relative to recent trading levels. Why Cencora (COR) Stock Is Up Today
• Negative Sentiment: Management indicated that a greater mix of GLP-1 products is weighing on margins, tempering the otherwise strong operating outlook. Cencora Sees Specialty Growth Continue While GLP-1 Mix Weighs on Margins
• Negative Sentiment: The Federal Trade Commission is taking a closer look at Cencora’s proposed Covetrus animal-health merger, adding regulatory uncertainty to the company’s acquisition strategy. FTC takes closer look at Cencora-Covetrus animal health merger

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.